Literature DB >> 16406183

Comparison of quantitative competitive polymerase chain reaction-enzyme-linked immunosorbent assay with LightCycler-based polymerase chain reaction for measuring cytomegalovirus DNA in patients after hematopoietic stem cell transplantation.

Marketa Pumannova1, Katerina Roubalova, Antonin Vitek, Jana Sajdova.   

Abstract

Development of highly sensitive quantitative assays for cytomegalovirus (CMV) DNA detection is crucial for identification of immunodeficient patients at high risk of CMV disease. We designed 2 internally controlled competitive quantitative assays, enzyme-linked immunosorbent assay (ELISA)-based and real-time polymerase chain reaction (PCR) tests, using amplification of the same segment of the CMV genome. The aim of this study was to compare sensitivity, specificity, and laboratory performance characteristics of these assays. In both assays, a 159-bp segment of UL83 gene was amplified. External and internal controls were constructed by cloning the amplification product and heterogenous DNA segment flanked by target sequences for CMV-derived primers into bacterial plasmids, respectively. Real-time PCR was performed on LightCycler (Roche Diagnostics, Mannheim, Germany), and amplicons were detected using fluorescence resonance energy transfer probes. Alternatively, PCR products were labeled by digoxigenin, hybridized to immobilized probes, and detected by ELISA. The assays were tested on genomic DNA isolated from laboratory strains of CMV, QCMD control panel, and CMV DNA-positive peripheral blood DNA samples from hematopoietic stem cell transplant recipients, previously characterized by pp65 antigenemia and qualitative nested PCR. Real-time and ELISA-based PCR assays showed a linear course of 1-10(8) and 10-10(5) copies of CMV DNA per reaction, respectively. When compared with ELISA-based PCR, real-time PCR showed superiority in inter- and intra-assay reproducibility. Both assays were highly specific in detecting CMV DNA. No difference in amplification efficiency of internal or external standards and wild-type CMV DNA was found. The assays exhibited 83% concordance in CMV DNA detection from clinical samples, all discrepant samples having low CMV DNA copy numbers. There was a good correlation between viral DNA loads measured by the 2 assays. Statistically significant correlation was observed between the numbers of CMV DNA copies and pp65-positive leukocytes in the samples tested. Both variants of competitive PCR are adequately sensitive to be used for CMV DNA quantitation in clinical samples. LightCycler PCR, having superior performance characteristics and being less time-consuming, seems to be more suitable for routine diagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16406183     DOI: 10.1016/j.diagmicrobio.2005.08.021

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

1.  Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients.

Authors:  Concepción Gimeno; Carlos Solano; José C Latorre; Juan C Hernández-Boluda; María A Clari; María J Remigia; Santiago Furió; Marisa Calabuig; Nuria Tormo; David Navarro
Journal:  J Clin Microbiol       Date:  2008-08-27       Impact factor: 5.948

2.  Comparative evaluation of three automated systems for DNA extraction in conjunction with three commercially available real-time PCR assays for quantitation of plasma Cytomegalovirus DNAemia in allogeneic stem cell transplant recipients.

Authors:  Dayana Bravo; María Ángeles Clari; Elisa Costa; Beatriz Muñoz-Cobo; Carlos Solano; María José Remigia; David Navarro
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

3.  Monitoring of cytomegalovirus reactivation in bone marrow transplant recipients by real-time PCR.

Authors:  Seyed H Ghaffari; Narghes Obeidi; Mehdi Dehghan; Kamran Alimoghaddam; Ahmad Gharehbaghian; Ardashir Ghavamzadeh
Journal:  Pathol Oncol Res       Date:  2008-04-08       Impact factor: 3.201

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.